TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Subjects Correctly Following Instructions for Use
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Ankle Dorsiflexion/Plantarflexion Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Ankle Inversion/Eversion Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Knee Flexion Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of reduction in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-heme Iron absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity and specificity of HD5 as marker for UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection rates of ureteric jets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: violent behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subsequent surgery after primary surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Probing depth change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of post-operative reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of ranibizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of HS with knowledge of vaccine recommendations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportions of HS regularly recommending vaccines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportions of HS with doubts about recommended vaccines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Thromboelastometric evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of Carboxyhemoglobin (COHb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in risk factors of cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in risk factors of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of CMV Disease or CMV Viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Swollen Joint Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tender Joint Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lymphedema Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Over Time in the Ability to Perceive Single Words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in the Signal-to-noise Ratio 50 (SNR-50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Fatigue Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: modified Lanza score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual Analog scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trinity Amputation and Prosthetic Experience Scales (TAPES)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Generalized Anxiety Disorder 7-item (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Permanent facial nerve palsy
Endpoint domain: Adverse events/effects
Primary endpoint: Major Adverse Kidney Event Within 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change from baseline on cognitive tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Psychological Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Remission From Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Outcomes Assessment for Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Minimal Disease Activity Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of navitoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global tolerability of Nyaditum resae ®, proportion of participants with adverse events related to study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of episodes of use of home pregnancy test kits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent Change in Synovitis Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Synovial B Cell Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Synovial Immunoglobulin (Ig) Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Suicidality via Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Analog Scale (VAS) Scores for Pain Perception
Endpoint domain: Adverse events/effects
Primary endpoint: Annual incidence rate of invasive pneumococcal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Measurement of aortic root at aortic valve annulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of aortic root at sinus of Valsalva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in the Assisting Hand Assessment (AHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancomycin clearance (Cl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution (Vd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hernia recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Depression Measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence and severity of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Skin Hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subjective Skin Hydration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maternal hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal bradycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurobehavioral and cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in retinol-binding protein/creatinine ratio (PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Moderate to severe radial artery spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Outcomes From Pregnancies With Reported Exposure Within 28 Days of Last Menstrual Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Outcomes From Pregnancies With Earliest Reported Exposure During the First Trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Outcomes From Pregnancies With Earliest Reported Exposure During the Second Trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Outcomes From Pregnancies With Earliest Reported Exposure During the Third Trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Centanafadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentration (Tmax) of Centanafadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration-time Curve From Time 0 to 12 Hours Postdose (AUC0-12h) of Centanafadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial blood flow differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in VAS leg score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left atrial thrombus resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Urine Monitoring Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrence of an Infarct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Choice of end-of-life place of care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Malonyl carnitine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tripalmitin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in social interaction behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Observable signs of well being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self reported mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Flap Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Proven or Probable Invasive Fungal Infection (IFI)
Endpoint domain: Adverse events/effects
Primary endpoint: blood hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: High Serum under-carboxylated osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean amount of intraoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physical Examination, Vital Signs and Safety Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Local Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Cytokine Laboratory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under plasma drug concentration-time curve [AUC(0-last), AUCinf]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmation of therapeutic targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Aldosterone-to-renin Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Temporary Neurologic Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Simulated driving performance errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CK values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score with ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half gastric emptying time t50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum fold increase in anti-HBsAg titer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportion of children with iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of children with anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence density of moderate-severe diarrhea episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: period prevalence of moderate-severe diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Light and Glare Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Best Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity and distribution in critical and non-critical organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left atrial appendage opening and depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of sPIF
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of sPIF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of sPIF on serum cPRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Successful and safe application of the ERAS 2.0 protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time in Rapid Eye Movement (REM) Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Time in slow wave sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Number of mature oocytes obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: IIEF EF domain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative Intraocular Pressure Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Ultrasound evaluation of the injury size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to play period
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Area Under the Curve (AUC[0-infinity]) of Tafenoquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject incidence of anti-AMG 876 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Macintosh Blade Length Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macintosh Blade Width Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-incisor Angle on Macintosh Blade Contact Point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of hepatitis A and tetanus vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Symptomatic Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-normalized Area under the Concentration-Time Curve (AUC) following oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-normalized Area under the Concentration-Time Curve (AUC) following intravenous dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of ocular and systemic adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: number of active trigger points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cervical range of motion angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum urinary flow (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Surgical Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of transfusion-associated microchimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of transfusion-associated microchimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Overall Disease Control Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: skin spot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Speech reception threshold in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Drinks Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Binge Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower extremity perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: dependance level
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Incidence of Treatment Discontinuations
Endpoint domain: Adverse events/effects
Primary endpoint: Scale of Contraversive Pushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Burke Lateropulsion Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catherine Bergago Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mesulam's symbol cancellation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Functional Impairment Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mini Nutritional Assessment (MNA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wrinkle severity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with wrinkle severity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Children with Diarrhea Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: One grade improvement on Depressor Anguli Oris Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Female Sexual Function Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with undetectable ctDNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Health Care System Hassles Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Metabolic Complete Response (CR) on Day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Therapeutic Window Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Therapeutic Electrical Energy Delivered (TEED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Daily Pre-dose Evening Peak Expiratory Flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference from baseline in urine leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inflammatory markers found in nasal brushings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in stool microbe relative abundances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biologic responses to the black raspberry (BRB) nectar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FACT-Fatigue Results
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Difference in Number of Patients Who Reached Target Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in Mean Daytime Systolic Ambulatory Blood Pressure From Baseline to Follow-up After Six Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes